# Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

> **NCT04717635** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Adult Onset Still's Disease

## Interventions

- **BIOLOGICAL:** Canakinumab

## Key facts

- **NCT ID:** NCT04717635
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-30
- **Primary completion:** 2025-04-16
- **Final completion:** 2025-04-16
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04717635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04717635, "Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04717635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*